BACKGROUND: Dendritic cells orchestrate pivotal immunological processes mediated by the production of cytokines and chemokines. OBJECTIVE: To assess whether neutralisation of tumour necrosis factor alpha (TNF alpha) during maturation of dendritic cells affects their phenotype and behaviour, which might explain the beneficial effects of TNF alpha neutralisation in rheumatoid arthritis. METHODS: Immature and fully matured dendritic cells were cultured from blood monocytes from patients with rheumatoid arthritis and healthy controls following standardised protocols. TNF alpha was neutralised by addition of the p55 soluble TNF alpha receptor, PEGsTNFRI. The effect of TNF alpha neutralisation on the phenotype (CD14, CD16, CD32, CD64, CD80, CD83, CD86, and MHC) of dendritic cells was investigated by flow cytometry. Expression of chemokines (CCL17, CCL18, CCL19, CCL22, CCL3, and CXCL8) and production of IL1 beta and IL6 during dendritic cell differentiation and maturation were examined. RESULTS: Neutralisation of TNF alpha during the differentiation and maturation of dendritic cells did not result in an altered dendritic cell phenotype in the rheumatoid patients or the healthy controls. In contrast, the expression of CCL17, CCL18, CCL19, CCL22, CCL3, and CXCL8 by dendritic cells was significantly reduced when TNF alpha activity was inhibited during lipopolysaccharide triggered dendritic cell maturation. The production of IL1 beta and IL6 by mature dendritic cells was inhibited by PEGsTNFRI. CONCLUSIONS: Inhibition of TNF alpha activity during dendritic cell maturation leads to the development of semi-mature cells. These data suggest a novel pathway by which the neutralisation of TNF alpha might exert its therapeutic effects.
BACKGROUND: Dendritic cells orchestrate pivotal immunological processes mediated by the production of cytokines and chemokines. OBJECTIVE: To assess whether neutralisation of tumour necrosis factor alpha (TNF alpha) during maturation of dendritic cells affects their phenotype and behaviour, which might explain the beneficial effects of TNF alpha neutralisation in rheumatoid arthritis. METHODS: Immature and fully matured dendritic cells were cultured from blood monocytes from patients with rheumatoid arthritis and healthy controls following standardised protocols. TNF alpha was neutralised by addition of the p55 soluble TNF alpha receptor, PEGsTNFRI. The effect of TNF alpha neutralisation on the phenotype (CD14, CD16, CD32, CD64, CD80, CD83, CD86, and MHC) of dendritic cells was investigated by flow cytometry. Expression of chemokines (CCL17, CCL18, CCL19, CCL22, CCL3, and CXCL8) and production of IL1 beta and IL6 during dendritic cell differentiation and maturation were examined. RESULTS: Neutralisation of TNF alpha during the differentiation and maturation of dendritic cells did not result in an altered dendritic cell phenotype in the rheumatoidpatients or the healthy controls. In contrast, the expression of CCL17, CCL18, CCL19, CCL22, CCL3, and CXCL8 by dendritic cells was significantly reduced when TNF alpha activity was inhibited during lipopolysaccharide triggered dendritic cell maturation. The production of IL1 beta and IL6 by mature dendritic cells was inhibited by PEGsTNFRI. CONCLUSIONS: Inhibition of TNF alpha activity during dendritic cell maturation leads to the development of semi-mature cells. These data suggest a novel pathway by which the neutralisation of TNF alpha might exert its therapeutic effects.
Authors: T B Geijtenbeek; R Torensma; S J van Vliet; G C van Duijnhoven; G J Adema; Y van Kooyk; C G Figdor Journal: Cell Date: 2000-03-03 Impact factor: 41.582
Authors: J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka Journal: Annu Rev Immunol Date: 2000 Impact factor: 28.527
Authors: R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky Journal: Lancet Date: 1999-12-04 Impact factor: 79.321
Authors: T R D J Radstake; R van der Voort; M ten Brummelhuis; M de Waal Malefijt; M Looman; C G Figdor; W B van den Berg; P Barrera; G J Adema Journal: Ann Rheum Dis Date: 2004-08-26 Impact factor: 19.103
Authors: J W van der Meer; S Endres; G Lonnemann; J G Cannon; T Ikejima; S Okusawa; J A Gelfand; C A Dinarello Journal: J Leukoc Biol Date: 1988-03 Impact factor: 4.962
Authors: T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema Journal: Ann Rheum Dis Date: 2005-05-05 Impact factor: 19.103
Authors: Ryan Galea; Hendrik J Nel; Meghna Talekar; Xiao Liu; Joshua D Ooi; Megan Huynh; Sara Hadjigol; Kate J Robson; Yi Tian Ting; Suzanne Cole; Karyn Cochlin; Shannon Hitchcock; Bijun Zeng; Suman Yekollu; Martine Boks; Natalie Goh; Helen Roberts; Jamie Rossjohn; Hugh H Reid; Ben J Boyd; Ravi Malaviya; David J Shealy; Daniel G Baker; Loui Madakamutil; A Richard Kitching; Brendan J O'Sullivan; Ranjeny Thomas Journal: JCI Insight Date: 2019-09-19
Authors: Jamal S Lewis; Natalia V Dolgova; Thomas J Chancellor; Abhinav P Acharya; Jerome V Karpiak; Tanmay P Lele; Benjamin G Keselowsky Journal: Biomaterials Date: 2013-09-03 Impact factor: 12.479
Authors: Antoine W T van Lieshout; Jaap Fransen; Marcel Flendrie; Agnes M M Eijsbouts; Frank H J van den Hoogen; Piet L C M van Riel; Timothy R D J Radstake Journal: Ann Rheum Dis Date: 2007-03-09 Impact factor: 19.103